MOLECULAR INHIBITION OF HIV TYPE-1 BY HIV TYPE-2 - EFFECTIVENESS IN PERIPHERAL-BLOOD MONONUCLEAR-CELLS

Citation
L. Alharthi et al., MOLECULAR INHIBITION OF HIV TYPE-1 BY HIV TYPE-2 - EFFECTIVENESS IN PERIPHERAL-BLOOD MONONUCLEAR-CELLS, AIDS research and human retroviruses, 14(1), 1998, pp. 59-64
Citations number
44
Categorie Soggetti
Immunology,"Infectious Diseases",Virology
ISSN journal
08892229
Volume
14
Issue
1
Year of publication
1998
Pages
59 - 64
Database
ISI
SICI code
0889-2229(1998)14:1<59:MIOHTB>2.0.ZU;2-I
Abstract
HIV-2 downregulates HIV-1 in human primary peripheral blood mononuclea r cells (PBMCs), Although the effect of HIV-2 on HIV-1 in human CD4(+) T cell lines was previously reported, the present observations with P BMCs are a necessary demonstration before considering animal model and clinical studies, Notably, the downregulation was observed with at le ast three phenotypically different HIV-1 proviruses and three differen t HIV-2 proviruses and was independent of the mode of introduction of the proviruses. HIV-2 inhibited both the production of extracellular H IV-1 p24 antigen and intracellular viral RNA, suggesting the involveme nt of transcriptional downmodulation, Some of the defective HIV-2 prov iruses also inhibited HIV-1. In some cases, these defects mere transco mplemented by the corresponding HIV-1 gene products, emphasizing cross -regulation between the two viruses, The phenotype of one of the mutan t HIV-2 proviruses suggested that the posttranscriptional effects may also occur, In addition to the possible HIV-2 suppression of HIV-1 in vivo by cross-protective immune mechanisms, intracellular inhibition, noted here, may be another line of defense, We have proposed that the inhibition may be the result of competition between HIV-1 and HIV-2 fo r cellular factors, possibly involving the long terminal repeats (LTRs ), For safety reasons, it may be advantageous to use subunits of HIV-2 for vaccines and gene therapy, HIV-2, specifically noncytopathic HIV- 2, could be viewed as an attenuated HIV-1 vaccination model, HIV-2-der ived gene transfer vectors may not only be inhibitory themselves but a lso allow for the insertion of additional protective genes to aim at m ultiple targets in the HIV-1 life cycle, thus curtailing the evolution of escape mutants.